Eli Lilly Stock: $1 Trillion and Novo Nordisk (LLY Stock Analysis NVO Stock Analysis)

Описание: Eli Lilly Analysis (LLY Stock Analysis) 2026 — Valuation, Price Targets & Earnings.

Eli Lilly surpassed a trillion-dollar market cap and $1,000 per share. This video analyzes its GLP-1 obesity market position with increased competition Novo Nordisk's (NVO Stock) obesity pills. We explore potential growth for Eli Lilly, optimal buying opportunities, and the impact of orforglipron, mounjaro and zepbound on its future in diabetes care.

What you’ll learn
-NVIDIA (NVDA Stock) AI lab Partnership
-Eli Lilly (LLY) vs Novo Nordisk (NVO) Revenue Mix
-Wall Street Analyst Estimates
-My plan, Bull Case, Bear Case, And Growth Drivers

▶️ Watch Next on my channel to level up your edge in the markets:
   • Stock Analysis: Price, Earnings, Valuation   (Valuation, Earnings, Estimates, Comps, Fundamentals, Technical Analysis)
   • Плейлист   (Stocks, Bonds, Crypto, Commodities, Volatility)

Timestamps
0:00 Why Eli Lilly Stock?
0:25 SPDR S&P 500 vs XLV Health Care Price Action
2:15 LLY News: Nvidia AI Lab Partnership
4:00 Novo Nordisk (NVO Stock) Ozempic and Wegovy Obesity Pills
5:40 Eli Lilly Revenue $100 Billion (Mounjaro, Zepbound, GLP-1)
8:30 Eli Lilly (LLY) versus Novo Nordisk (NVO)

Resources mentioned
• Eli Lilly Investor Relations — latest earnings release & presentation ($LLY)
• KoyFin Tutorial, Fiscal.AI Tutorial, TradingView Tutorial
• Eli Lilly Earnings call transcript — guidance and commentary
• SEC filings (10-Q / 10-K) — Income Statement, Balance Sheet, Cash Flow Statement
• Analyst estimate trends & revisions — Revenue, EBITDA, EPS, Price Target, Growth Rates

👍 If you enjoyed watching, subscribe for more forward-looking analysis (not news recaps). I share my top-down context with individual technical analysis setups and valuation targets so you know what moves the markets.

#stocks #stockmarket #stocksanalysis #stockstobuy #investing

DISCLAIMER
The information contained in this video is for educational and entertainment purposes only and does not constitute financial, investment, or trading advice. Always do your own research or consult a licensed financial professional before making any investment decisions. The views expressed are my own and may include opinions, estimates, and projections that do not guarantee future results.